Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Int J Infect Dis ; 104: 242-249, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33326874

RESUMO

BACKGROUND: Susceptibility to Covid-19 has been found to be associated with the ABO blood group, with O type individuals being at a lower risk. However, the underlying mechanism has not been elucidated. Here, we aimed to test the hypothesis that Covid-19 patients might have lower levels of ABO antibodies than non-infected individuals as they could offer some degree of protection. METHODS: After showing that the viral spike protein harbors the ABO glycan epitopes when produced by cells expressing the relevant glycosyltransferases, like upper respiratory tract epithelial cells, we enrolled 290 patients with Covid-19 and 276 asymptomatic controls to compare their levels of natural ABO blood group antibodies. RESULTS: We found significantly lower IgM anti-A + anti-B agglutination scores in blood group O patients (76.93 vs 88.29, P-value = 0.034) and lower levels of anti-B (24.93 vs 30.40, P-value = 0.028) and anti-A antibodies (28.56 vs 36.50, P-value = 0.048) in blood group A and blood group B patients, respectively, compared to controls. CONCLUSION: In this study, we showed that ABO antibody levels are significantly lower in Covid-19 patients compared to controls. These findings could indicate that patients with low levels of ABO antibodies are at higher risk of being infected.


Assuntos
Sistema ABO de Grupos Sanguíneos/imunologia , Anticorpos/sangue , COVID-19/sangue , Polissacarídeos/imunologia , SARS-CoV-2/imunologia , Glicoproteína da Espícula de Coronavírus/imunologia , Adulto , Idoso , Idoso de 80 Anos ou mais , COVID-19/virologia , Suscetibilidade a Doenças , Células Epiteliais/imunologia , Epitopos/imunologia , Feminino , Galactosiltransferases , Humanos , Imunoglobulina M/imunologia , Masculino , Pessoa de Meia-Idade , Risco , Adulto Jovem
2.
Transplantation ; 73(12): 1974-6, 2002 Jun 27.
Artigo em Inglês | MEDLINE | ID: mdl-12131703

RESUMO

BACKGROUND: Conversion after transplantation from cyclosporine to tacrolimus is often performed because of recurrent acute/chronic rejection or unacceptable side effects such as nephrotoxicity, arterial hypertension, and cosmetic disorders. Although gastrointestinal discomfort is often reported after transplantation, it is usually not considered a sufficient reason for conversion, although tacrolimus seems beneficial with regards to gastric motor activity in renal transplant patients. METHODS: A lung transplantation was performed in a 41-year-old woman with alpha-1 antitrypsin deficiency emphysema. Because the patient presented severe symptoms of nausea, vomiting, and dyspepsia, without obvious endoscopic explanation, that resulted in highly variable cyclosporine trough levels, she was converted from cyclosporine to tacrolimus. RESULTS: After conversion, dyspepsia, nausea, and vomiting resolved. Neurological complications caused by a transient high trough level of tacrolimus resolved completely upon dose reduction with tacrolimus trough levels remaining very stable afterwards. CONCLUSION: Tacrolimus may be the immunosuppressant of choice after solid organ transplantation in patients with problems related to gastric motor dysfunction.


Assuntos
Ciclosporina/efeitos adversos , Imunossupressores/uso terapêutico , Transplante de Pulmão/efeitos adversos , Gastropatias/prevenção & controle , Tacrolimo/uso terapêutico , Adulto , Feminino , Motilidade Gastrointestinal/efeitos dos fármacos , Humanos , Gastropatias/induzido quimicamente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA